

**QP CODE: 113328**

**Reg. No:.....**

**First Semester M.Pharm Degree Regular/Supplementary Examinations  
April 2025**

**M.Pharm (Pharmacology)**

**Paper III – Pharmacological and Toxicological Screening Methods I  
(MPL103T)**

**(Common for 2019 and 2024 Scheme)**

**Time: 3 Hours**

**Total Marks: 75**

- *Answer all questions to the point neatly and legibly • Do not leave any blank pages between answers • Indicate the question number correctly for the answer in the margin space*
- *Answer all parts of a single question together • Leave sufficient space between answers*
- *Draw table/diagrams/flow charts wherever necessary*

**Essays**

**(3x10=30)**

1. Describe briefly about CPCSEA guidelines.
2. Enlist the in-vivo and in-vitro screening models of anti-depressants activity. Explain any one method for each.
3. Explain various preclinical employed in the evaluation of anti-inflammatory drugs.

**Short Notes**

**(9x5=45)**

4. Compare and contrast heterogeneous and homogenous immunoassay systems.
5. Enumerate preclinical models employed in the evaluation of cardiovascular drugs and explain any one of them.
6. What is euthanasia. Explain the methods of euthanasia.
7. How will you evaluate the drugs used for Parkinson's disease.
8. Explain any three preclinical screening models for evaluation of anticancer agents.
9. Explain any two pharmacological screening methods for COPD.
10. Explain the principle and procedure involved in pylorus ligation technique.
11. Enlist the limitations of animal experimentation and alternative animal experiments.
12. Enlist the in-vivo and in-vitro screening models for immunosuppressant and immunostimulants.

\*\*\*\*\*